204910-49-6 Usage
Description
3-(2-Thienyl)-5-isoxazolecarboxylic Acid is an organic compound that features a thiophene ring and an isoxazole ring, making it a valuable building block in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups provide a versatile platform for the development of new drugs and materials.
Uses
Used in Pharmaceutical Industry:
3-(2-Thienyl)-5-isoxazolecarboxylic Acid is used as a key intermediate in the synthesis of oxazolidinone antibacterial agents, which are a class of antibiotics effective against a wide range of bacterial infections. The incorporation of substituted isoxazoles in these agents enhances their potency and broadens their spectrum of activity, making them valuable tools in the fight against antibiotic-resistant bacteria.
Check Digit Verification of cas no
The CAS Registry Mumber 204910-49-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,4,9,1 and 0 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 204910-49:
(8*2)+(7*0)+(6*4)+(5*9)+(4*1)+(3*0)+(2*4)+(1*9)=106
106 % 10 = 6
So 204910-49-6 is a valid CAS Registry Number.
204910-49-6Relevant articles and documents
COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY
-
Paragraph 0233, (2017/02/24)
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).
COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
-
Paragraph 0259, (2016/07/27)
The present disclosure is directed to disclosed compounds that increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
